Belimumab
Based on 6 publication(s) in Google Scholar
Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research. The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.4%
- No. CAS: 356547-88-1
- Peso molecular:144.54 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Belimumab
More- Leukemia. 2025 Aug 1. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2026 Nov;1872(8):168342.
- Clin Immunol. 2023 Sep:254:109687. [Abstract]
- Immunopharmacol Immunotoxicol. 2025 Jul 30:1-11. [Abstract]
- Kaohsiung J Med Sci. 2023 Dec;39(12):1200-1212. [Abstract]
- bioRxiv. 2025 Nov 25:2025.11.22.689920. [Abstract]
-
Flow Cytometry
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
Isotype
Human IgG1 lambda2
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TNFSF13B/BAFF/CD257
In Vivo
Single-Dose Pharmacokinetics of i.v. Belimumab in Cynomolgus Monkeys[3]
| Parameters | Cmax (μg/mL) | AUC0-∞ (day μg/mL) | V1 (mL/kg) | Vss (mL/kg) | CL (mL/day/kg) | T1/2,α (day) | T1/2,term (day) | MRT (day) |
| 5 mg/kg (n=4) | 111±2 | 901±40 | 45.0±0.7 | 85.0±2.1 | 5.6±0.2 | 0.52±0.13 | 11.2±0.7 | 15.4±1.0 |
| 50 mg/kg (n=3) | 1230±180 | 8970±320 | 42.4±5.9 | 108±14 | 5.6±0.2 | 0.44±0.20 | 14.0±1.8 | 19.1±2.1 |
| 150 mg/kg (n=3) | 3778±326 | 22,693±3990 | 39.7±3.3 | 89.8±11.4 | 6.8±1.3 | 0.41±0.55 | 11.5±1.7 | 13.7±3.5 |